Kelonia Unveils First-in-Human In Vivo BCMA CAR-T Data at ASH 2025
Kelonia Therapeutics Announces Late-Breaking Oral Presentation Showcasing First-in-Human Data for KLN-1010, an In Vivo BCMA CAR-T Gene Therapy, at ASH 2025 Kelonia Therapeutics, Inc., a clinical-stage biotechnology company advancing a…
Microsize and Schedio Group Announce Acquisition of Lonza’s Micro-Macinazione Facility in Switzerland
Microsize and Schedio Group Sign Agreement to Acquire Lonza’s Micro-Macinazione Facility in Switzerland, Advancing a Transatlantic Particle Engineering Platform Microsize, a prominent contract development and manufacturing organization (CDMO) known for…
AstraZeneca to Invest $2B in Maryland Manufacturing, Create 2,600 Jobs
AstraZeneca Announces $2 Billion Expansion to Strengthen Maryland Manufacturing, Advance Innovation, and Support 2,600 Jobs AstraZeneca today unveiled a major strategic investment plan totaling $2 billion to expand its long-standing…
U.S. FDA Grants Approval to PADCEV® and Keytruda® Combination for Select Bladder Cancer Patients
FDA Authorizes PADCEV® + Keytruda® Regimen for Eligible Individuals with Bladder Cancer Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503; President and CEO: Naoki Okamura, “Astellas”) announced that…
Parabilis Medicines Reports Encouraging Early FOG-001 Data in ACP at SNO 2025
Parabilis Medicines Announces Compelling Preliminary Clinical Results for FOG-001 in Adamantinomatous Craniopharyngioma at SNO 2025 Parabilis Medicines, a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with cancer,…
Blue Lake Biotech to Resume Enrollment in BLB201 Toddler Trial
Blue Lake Biotechnology Announces FDA Clearance to Resume Enrollment of RSV-Negative and Younger Toddlers in Phase 1/2a Clinical Trial of BLB201 Blue Lake Biotechnology, Inc., a clinical-stage company pioneering intranasal…
AGC Biologics to Produce AAVantgarde’s Dual-Vector Gene Therapies
AGC Biologics and AAVantgarde Forge New Manufacturing Partnership to Advance Dual-Vector Gene Therapies for Inherited Retinal Diseases Following AAVantgarde Bio’s recent completion of a successful Series B financing round, the…
BeOne Medicines Highlights Advances in B-Cell Malignancy Treatments at ASH 2025
BeOne Medicines Demonstrates Scientific Leadership in B-Cell Cancers at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a rapidly expanding global oncology innovator, is set to showcase…
Quanterix Announces Strategic Board and Leadership Transitions to Accelerate Future Growth
Quanterix Announces Comprehensive Board and Leadership Enhancements to Accelerate Its Next Phase of Strategic Growth Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in ultrasensitive biomarker detection…
Contineum Therapeutics Releases Phase 2 RRMS Trial Results for PIPE-307
Contineum Therapeutics Reports Topline Data From Phase 2 VISTA Trial Evaluating PIPE-307 in Relapsing-Remitting Multiple Sclerosis Contineum Therapeutics, Inc. (NASDAQ: CTNM) (“Contineum” or the “Company”), a clinical-stage biopharmaceutical organization advancing…
Hercules Pharmaceuticals Joins Healthcare Distribution Alliance; Timothy Ward Appointed to Board
Hercules Pharmaceuticals Announces Membership in the Healthcare Distribution Alliance and Board Appointment of Timothy Ward Hercules Pharmaceuticals (Hercules), a national leader in pharmaceutical distribution and a rapidly growing provider-aligned group…
ZIIHERA® + TEVIMBRA® Shows Strong Phase 3 Results in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Announces Positive Phase 3 HERIZON-GEA-01 Results Supporting ZIIHERA®-Based Regimens as Transformative First-Line Options for HER2-Positive Gastroesophageal Adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global…